Stephanie Morris

Stephanie joined Artesian in 2023. As Principal, Stephanie leads the end-to-end venture investment process and strategy for companies in the SAVC Fund and Health Transformation vertical across Artesian. Stephanie has an extensive background in deep tech commercialisation, particularly in life sciences.

Prior to joining Artesian, Stephanie worked as Director of Innovation & Translation at MTPConnect, and spent 5 years at Imperial College London as Director of Industry Partnerships & Commercialisation, Medicine and later as expert independent consultant. She also serves as consultant to TenU, hosted by the University of Cambridge. Stephanie brings experience from across the full commercialisation continuum including research, clinical development and technology translation, licensing, spinout formation and investment.

Stephanie holds an MBA from the University of South Australia, is a Graduate of the Australian Institute of Company Directors (GAICD), a Certified Licensing Professional (CLP) and has tertiary qualifications in both Business and Biomedical Science. She also currently serves on the board for BiomeBank and Ferronova and previously served as Deputy Chair for the Cure4CF Foundation